• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SCHEDULE 13G/A filed by TELA Bio Inc.

    5/30/25 4:03:12 PM ET
    $TELA
    Medical/Dental Instruments
    Health Care
    Get the next $TELA alert in real time by email



    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549


    SCHEDULE 13G


    UNDER THE SECURITIES EXCHANGE ACT OF 1934
    (Amendment No. 1)


    TELA Bio, Inc.

    (Name of Issuer)


    Common Stock, $0.001 par value per share

    (Title of Class of Securities)


    872381108

    (CUSIP Number)


    03/31/2025

    (Date of Event Which Requires Filing of this Statement)


    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
    Checkbox not checked   Rule 13d-1(b)
    Checkbox checked   Rule 13d-1(c)
    Checkbox not checked   Rule 13d-1(d)






    SCHEDULE 13G

    CUSIP No.
    872381108


    1Names of Reporting Persons

    North Run Capital, LP
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    3,682,489.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    3,682,489.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    3,682,489.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    9.3 %
    12Type of Reporting Person (See Instructions)

    PN


    SCHEDULE 13G

    CUSIP No.
    872381108


    1Names of Reporting Persons

    North Run Advisors, LLC
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    3,682,489.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    3,682,489.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    3,682,489.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    9.3 %
    12Type of Reporting Person (See Instructions)

    OO


    SCHEDULE 13G

    CUSIP No.
    872381108


    1Names of Reporting Persons

    North Run - Due North Partners, LP
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    3,682,489.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    3,682,489.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    3,682,489.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    9.3 %
    12Type of Reporting Person (See Instructions)

    PN


    SCHEDULE 13G

    CUSIP No.
    872381108


    1Names of Reporting Persons

    North Run GP, LP
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    3,682,489.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    3,682,489.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    3,682,489.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    9.3 %
    12Type of Reporting Person (See Instructions)

    PN


    SCHEDULE 13G

    CUSIP No.
    872381108


    1Names of Reporting Persons

    Todd B. Hammer
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    UNITED STATES
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    3,682,489.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    3,682,489.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    3,682,489.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    9.3 %
    12Type of Reporting Person (See Instructions)

    IN


    SCHEDULE 13G

    CUSIP No.
    872381108


    1Names of Reporting Persons

    Thomas B. Ellis
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    UNITED STATES
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    3,682,489.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    3,682,489.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    3,682,489.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    9.3 %
    12Type of Reporting Person (See Instructions)

    IN


    SCHEDULE 13G

    CUSIP No.
    872381108


    1Names of Reporting Persons

    Michael Bosco
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    UNITED STATES
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    3,682,489.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    3,682,489.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    3,682,489.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    9.3 %
    12Type of Reporting Person (See Instructions)

    IN


    SCHEDULE 13G

    Item 1. 
    (a)Name of issuer:

    TELA Bio, Inc.
    (b)Address of issuer's principal executive offices:

    1 Great Valley Parkway, Suite 24, Malvern, PA 19355
    Item 2. 
    (a)Name of person filing:

    This Schedule 13G is being filed on behalf of North Run Capital, LP, a Delaware limited partnership (the "Investment Manager"), North Run Advisors, LLC, a Delaware limited liability company ("North Run"), North Run - Due North Partners, LP, a Delaware limited partnership ("Due North"), North Run GP, LP, a Delaware limited partnership (the "GP"), Todd B. Hammer, Thomas B. Ellis and Michael Bosco (collectively, the "Reporting Persons"). The Investment Manager is the investment manager of certain private pooled investment vehicles, including Due North. Todd B. Hammer, Thomas B. Ellis and Michael Bosco are the limited partners of Due North. This Schedule 13G relates to shares of Common Stock, par value $0.001 per share (the "Common Stock"), of TELA Bio, Inc., a Delaware corporation (the "Issuer"), held by the Due North.
    (b)Address or principal business office or, if none, residence:

    For all Filers: 867 Boylston St., 5th Floor #1361, Boston, MA 02116.
    (c)Citizenship:

    (1) North Run Capital, LP is a Delaware limited partnership. (2) North Run Advisors, LLC is a Delaware limited liability company. (3) North Run - Due North Partners, LP is a Delaware limited partnership. (4) North Run GP, LP is a Delaware limited partnership. (5) Todd B. Hammer is a U.S. citizen. (6) Thomas B. Ellis is a U.S. citizen. (7) Michael Bosco is a U.S. citizen.
    (d)Title of class of securities:

    Common Stock, $0.001 par value per share
    (e)CUSIP No.:

    872381108
    Item 3.If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
    (a)Checkbox not checked   Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
    (b)Checkbox not checked   Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
    (c)Checkbox not checked   Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
    (d)Checkbox not checked   Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
    (e)Checkbox not checked   An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
    (f)Checkbox not checked   An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
    (g)Checkbox not checked   A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
    (h)Checkbox not checked   A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
    (i)Checkbox not checked   A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
    (j)Checkbox not checked   A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
           please specify the type of institution:
    (k)Checkbox not checked   Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
     
    Item 4.Ownership
    (a)Amount beneficially owned:

    The Investment Manager, North Run, Todd B. Hammer, Thomas B. Ellis, Michael Bosco, Due North and the GP may be deemed the beneficial owners of 3,682,489 shares of Common Stock as of March 31, 2025.
    (b)Percent of class:

    The Investment Manager, North Run, Todd B. Hammer, Thomas B. Ellis, Michael Bosco, Due North and the GP may be deemed the beneficial owners of approximately 9.3% of the outstanding shares of Common Stock as of March 31, 2025. The percent of class is based upon 39,554,771 shares of Common Stock outstanding as of March 31, 2025, as reported in the Issuer's Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on May 8, 2025.
    (c)Number of shares as to which the person has:
     (i) Sole power to vote or to direct the vote:

    Not applicable.

     (ii) Shared power to vote or to direct the vote:

    The Investment Manager, North Run, Todd B. Hammer, Thomas B. Ellis, Michael Bosco, Due North and the GP have the shared power to vote the 3,682,489 shares of Common Stock beneficially owned as of March 31, 2025.

     (iii) Sole power to dispose or to direct the disposition of:

    Not applicable.

     (iv) Shared power to dispose or to direct the disposition of:

    The Investment Manager, North Run, Todd B. Hammer, Thomas B. Ellis, Michael Bosco, Due North and the GP have the shared power to dispose of the 3,682,489 shares of Common Stock beneficially owned as of March 31, 2025.

    Item 5.Ownership of 5 Percent or Less of a Class.
     
    Item 6.Ownership of more than 5 Percent on Behalf of Another Person.
     
    Not Applicable
    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
     
    Not Applicable
    Item 8.Identification and Classification of Members of the Group.
     
    Not Applicable
    Item 9.Notice of Dissolution of Group.
     
    Not Applicable

    Item 10.Certifications:
     
    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

        SIGNATURE 
     
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     
    North Run Capital, LP
     
    Signature:/s/ Michael Fisher
    Name/Title:Michael Fisher / Attorney-in-Fact for Thomas B. Ellis and Todd B. Hammer, Members of General Partner
    Date:05/30/2025
     
    North Run Advisors, LLC
     
    Signature:/s/ Michael Fisher
    Name/Title:Michael Fisher / Attorney-in-Fact for Thomas B. Ellis and Todd B. Hammer, Members
    Date:05/30/2025
     
    North Run - Due North Partners, LP
     
    Signature:/s/ Michael Fisher
    Name/Title:Michael Fisher/ Attorney-in-Fact for Thomas B. Ellis, Todd B. Hammer and Michael Bosco Members of General Partner
    Date:05/30/2025
     
    North Run GP, LP
     
    Signature:/s/ Michael Fisher
    Name/Title:Michael Fisher / Attorney-in-Fact for Thomas B. Ellis and Todd B. Hammer, Members of General Partner
    Date:05/30/2025
     
    Todd B. Hammer
     
    Signature:/s/ Michael Fisher
    Name/Title:Michael Fisher, Attorney-in-Fact
    Date:05/30/2025
     
    Thomas B. Ellis
     
    Signature:/s/ Michael Fisher
    Name/Title:Michael Fisher, Attorney-in-Fact
    Date:05/30/2025
     
    Michael Bosco
     
    Signature:/s/ Michael Fisher
    Name/Title:Michael Fisher, Attorney-in-Fact
    Date:05/30/2025
    Get the next $TELA alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $TELA

    DatePrice TargetRatingAnalyst
    3/21/2025$5.00 → $2.00Overweight → Neutral
    Piper Sandler
    5/31/2022$17.00Buy
    Lake Street
    More analyst ratings

    $TELA
    Financials

    Live finance-specific insights

    See more
    • TELA Bio Reports First Quarter 2025 Financial Results

      MALVERN, Pa., May 08, 2025 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio"), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today reported financial results for the first quarter ended March 31, 2025. Recent Highlights Delivered revenue of $18.5 million in the first quarter 2025, representing growth of 12% over the prior year period and sequential growth of 5% over the fourth quarter of 2024;Increased demand for OviTex® and OviTex PRS Reinforced Tissue Matrix products during the first quarter, resulting in year-over-year revenue increase for each product of approximately 15% and 2%, respectively;Commenced full U.S. comme

      5/8/25 4:05:00 PM ET
      $TELA
      Medical/Dental Instruments
      Health Care
    • TELA Bio to Announce First Quarter 2025 Financial Results

      MALVERN, Pa., April 17, 2025 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio") (NASDAQ:TELA), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today announced that the Company will report first quarter 2025 financial results on Thursday, May 8, 2025. TELA Bio's management will host a conference call and webcast at 4:30 p.m. ET that day to discuss the financial results and provide a corporate update. First Quarter Earnings Conference Call and Webcast DetailsInvestors interested in listening to the conference call should register online. Participants are required to register a day in advance or at minimum 15 minutes before the

      4/17/25 4:05:00 PM ET
      $TELA
      Medical/Dental Instruments
      Health Care
    • TELA Bio Reports Fourth Quarter and Full Year 2024 Financial Results

      MALVERN, Pa., March 20, 2025 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio"), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today reported financial results for the fourth quarter and full year ended December 31, 2024. Recent Highlights Delivered revenue of $17.6 million in the fourth quarter and $69.3 million for the full year 2024, representing growth of 4% and 19%, respectively, over the corresponding periods of 2023;Increased demand for OviTex® and OviTex PRS Reinforced Tissue Matrix products during the full year 2024, resulting in growth in unit sales volume for each product of approximately 33% and 31%, r

      3/20/25 4:05:00 PM ET
      $TELA
      Medical/Dental Instruments
      Health Care

    $TELA
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • TELA Bio downgraded by Piper Sandler with a new price target

      Piper Sandler downgraded TELA Bio from Overweight to Neutral and set a new price target of $2.00 from $5.00 previously

      3/21/25 8:05:03 AM ET
      $TELA
      Medical/Dental Instruments
      Health Care
    • Lake Street initiated coverage on TELA Bio with a new price target

      Lake Street initiated coverage of TELA Bio with a rating of Buy and set a new price target of $17.00

      5/31/22 9:13:36 AM ET
      $TELA
      Medical/Dental Instruments
      Health Care

    $TELA
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • TELA Bio Announces European Commercial Launch of OviTex® Inguinal for Robotic and Laparoscopic Inguinal Hernia Repair

      MALVERN, Pa., June 03, 2025 (GLOBE NEWSWIRE) -- TELA Bio, Inc. (NASDAQ:TELA), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today announced the European launch of OviTex Inguinal Reinforced Tissue Matrix, the only reinforced tissue matrix specifically engineered for laparoscopic and robotic-assisted inguinal hernia repair. This milestone follows the successful U.S. launch of OviTex Inguinal in 2024, where it has achieved over $1 million in sales in its first year and has seen growing adoption by surgeons seeking a tailored, more natural alternative to synthetic mesh for inguinal hernia procedures. OviTex Inguinal is av

      6/3/25 4:05:00 PM ET
      $TELA
      Medical/Dental Instruments
      Health Care
    • TELA Bio Appoints Jeffrey Blizard as President

      MALVERN, Pa., June 02, 2025 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio"), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today announced the appointment of Jeffrey Blizard as President of TELA Bio, effective immediately. Mr. Blizard, who has served on TELA Bio's Board of Directors for the past year, brings deep industry experience and proven leadership to this expanded role. "This is an important inflection point for TELA Bio," said Antony Koblish, Co-Founder and Chief Executive Officer of TELA Bio. "As we move into the next phase of our growth trajectory, we believe the addition of Jeff—a highly respected l

      6/2/25 8:30:00 AM ET
      $TELA
      Medical/Dental Instruments
      Health Care
    • TELA Bio to Participate in the 2025 Jefferies Global Healthcare Conference

      MALVERN, Pa., May 22, 2025 (GLOBE NEWSWIRE) -- TELA Bio, Inc. (NASDAQ:TELA), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today announced that the Company will participate in the 2025 Jefferies Global Healthcare Conference. TELA's management is scheduled to present at the 2025 Jefferies Global Healthcare Conference at 11:05 am ET on June 5th, 2025. Interested parties can access the live and archived webcast at ir.telabio.com. About TELA Bio, Inc.TELA Bio, Inc. (NASDAQ:TELA) is a commercial-stage medical technology company focused on providing innovative technologies that optimize clinical outcomes by prioritizing the

      5/22/25 4:05:00 PM ET
      $TELA
      Medical/Dental Instruments
      Health Care

    $TELA
    SEC Filings

    See more
    • TELA Bio Inc. filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits

      8-K - TELA Bio, Inc. (0001561921) (Filer)

      6/2/25 8:30:24 AM ET
      $TELA
      Medical/Dental Instruments
      Health Care
    • TELA Bio Inc. filed SEC Form 8-K: Leadership Update, Submission of Matters to a Vote of Security Holders

      8-K - TELA Bio, Inc. (0001561921) (Filer)

      5/30/25 4:06:00 PM ET
      $TELA
      Medical/Dental Instruments
      Health Care
    • Amendment: SEC Form SCHEDULE 13G/A filed by TELA Bio Inc.

      SCHEDULE 13G/A - TELA Bio, Inc. (0001561921) (Subject)

      5/30/25 4:03:12 PM ET
      $TELA
      Medical/Dental Instruments
      Health Care

    $TELA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • President Blizard Jeffrey was granted 104,800 shares, increasing direct ownership by 732% to 119,125 units (SEC Form 4)

      4 - TELA Bio, Inc. (0001561921) (Issuer)

      6/2/25 4:59:08 PM ET
      $TELA
      Medical/Dental Instruments
      Health Care
    • Director Evans Douglas G was granted 7,950 shares, increasing direct ownership by 76% to 18,470 units (SEC Form 4)

      4 - TELA Bio, Inc. (0001561921) (Issuer)

      5/30/25 4:18:35 PM ET
      $TELA
      Medical/Dental Instruments
      Health Care
    • Director O'Brien Federica F. was granted 7,950 shares, increasing direct ownership by 76% to 18,470 units (SEC Form 4)

      4 - TELA Bio, Inc. (0001561921) (Issuer)

      5/30/25 4:18:27 PM ET
      $TELA
      Medical/Dental Instruments
      Health Care

    $TELA
    Leadership Updates

    Live Leadership Updates

    See more
    • TELA Bio Appoints Jeffrey Blizard as President

      MALVERN, Pa., June 02, 2025 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio"), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today announced the appointment of Jeffrey Blizard as President of TELA Bio, effective immediately. Mr. Blizard, who has served on TELA Bio's Board of Directors for the past year, brings deep industry experience and proven leadership to this expanded role. "This is an important inflection point for TELA Bio," said Antony Koblish, Co-Founder and Chief Executive Officer of TELA Bio. "As we move into the next phase of our growth trajectory, we believe the addition of Jeff—a highly respected l

      6/2/25 8:30:00 AM ET
      $TELA
      Medical/Dental Instruments
      Health Care
    • TELA Bio Appoints Jeffrey Blizard to its Board of Directors

      MALVERN, Pa., June 04, 2024 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio") (NASDAQ:TELA), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today announced that it has appointed Jeffrey Blizard, the Global Head of Surgical Sales for Abiomed, a medical device technology company that operates as a stand-alone business within Johnson & Johnson's MedTech Segment, to its Board of Directors, effective June 4, 2024. "We are excited to have Jeff join our Board as we continue to develop and optimize our sales force," said Antony Koblish, co-founder, President and Chief Executive Officer of TELA Bio. "Jeff's exceptional sales leader

      6/4/24 4:05:00 PM ET
      $TELA
      Medical/Dental Instruments
      Health Care
    • TELA Bio Appoints Greg Firestone as Chief Commercial Officer

      MALVERN, Pa., May 20, 2024 (GLOBE NEWSWIRE) -- TELA Bio, Inc. (NASDAQ:TELA), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today announced the appointment of Greg Firestone as the Company's new Chief Commercial Officer. In this role, Mr. Firestone will oversee the Company's commercial operations, including key product launches, sales team training, market development, as well as strategic initiatives to optimize market access and reimbursement strategy across the Company's product lines. "Greg has been an instrumental player in the TELA Bio story, supporting our commercial strategy and cultivating each of our key group

      5/20/24 4:03:00 PM ET
      $TELA
      Medical/Dental Instruments
      Health Care

    $TELA
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • COO and CFO Cuca Roberto bought $144,999 worth of shares (64,444 units at $2.25), increasing direct ownership by 71% to 155,388 units (SEC Form 4)

      4 - TELA Bio, Inc. (0001561921) (Issuer)

      10/24/24 4:26:40 PM ET
      $TELA
      Medical/Dental Instruments
      Health Care
    • Chief Technology Officer Talmo Paul bought $50,000 worth of shares (22,222 units at $2.25), increasing direct ownership by 32% to 91,082 units (SEC Form 4)

      4 - TELA Bio, Inc. (0001561921) (Issuer)

      10/24/24 4:25:59 PM ET
      $TELA
      Medical/Dental Instruments
      Health Care
    • Chief Executive Officer Koblish Antony bought $199,998 worth of shares (88,888 units at $2.25), increasing direct ownership by 24% to 458,897 units (SEC Form 4)

      4 - TELA Bio, Inc. (0001561921) (Issuer)

      10/24/24 4:25:31 PM ET
      $TELA
      Medical/Dental Instruments
      Health Care

    $TELA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by TELA Bio Inc.

      SC 13G/A - TELA Bio, Inc. (0001561921) (Subject)

      11/14/24 1:06:57 PM ET
      $TELA
      Medical/Dental Instruments
      Health Care
    • SEC Form SC 13G filed by TELA Bio Inc.

      SC 13G - TELA Bio, Inc. (0001561921) (Subject)

      10/29/24 5:12:40 PM ET
      $TELA
      Medical/Dental Instruments
      Health Care
    • Amendment: SEC Form SC 13G/A filed by TELA Bio Inc.

      SC 13G/A - TELA Bio, Inc. (0001561921) (Subject)

      10/28/24 4:06:51 PM ET
      $TELA
      Medical/Dental Instruments
      Health Care